RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer Response

被引：0
|
作者：
Wang, Xinan [1 ,2 ]
Ricciuti, Biagio [3 ,4 ]
Alessi, Joao, V [3 ,4 ]
Nguyen, Tom [3 ,4 ]
Awad, Mark M. [3 ,4 ]
Lin, Xihong [5 ]
Johnson, Bruce E. [3 ,4 ]
Christiani, David C. [2 ,6 ]
机构：
[1] Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA
[2] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 667 Huntington Ave, Boston, MA 02115 USA
[3] Harvard Med Sch, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[4] Harvard Med Sch, Ctr Canc Gen, Dana Farber Canc Inst, Boston, MA USA
[5] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2022年 / 114卷 / 03期
关键词：
D O I：
10.1093/jnci/djab161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：477 / 478
页数：2
相关论文
共 50 条
  • [1] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Hopkins, Ashley M.
    Kichenadasse, Ganessan
    Logan, Jessica M.
    Rowland, Andrew
    Sorich, Michael J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 475 - 476
  • [2] Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao, V
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (12): : 1761 - 1769
  • [3] Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC).
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao V.
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
    Pirker, Robert
    ESMO OPEN, 2018, 3 (05)
  • [5] Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients
    Kubo, T.
    Watanabe, H.
    Ninomiya, K.
    Kudo, K.
    Minami, D.
    Murakami, E.
    Ochi, N.
    Ninomiya, T.
    Harada, D.
    Yasugi, M.
    Ichihara, E.
    Ohashi, K.
    Fujiwara, K.
    Hotta, K.
    Tabata, M.
    Maeda, Y.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients
    Kubo, Toshio
    Watanabe, Hiromi
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Rai, Kammei
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1447 - 1453
  • [7] Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer
    Christopoulos, P.
    Kohlhaeufl, J.
    Bozorgmehr, F.
    Kuon, J.
    Schneider, M.
    Neumann, O.
    Liersch, S.
    Heussel, C.
    Winter, H.
    Herth, F.
    Rieken, S.
    Muley, T.
    Meister, M.
    Bischoff, H.
    Lasitschka, F.
    Stenzinger, A.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
    Spakowicz, D.
    Williams, N.
    Bibi, A.
    Hoyd, R.
    Wheeler, C. E.
    Suman, S.
    Amann, J.
    Okimoto, T.
    Grogan, M.
    Vibhakar, P.
    Owen, D.
    Carbone, D. P.
    Presley, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S345 - S346
  • [9] Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
    Corke, Lucy K.
    Li, Janice J. N.
    Leighl, Natasha B.
    Eng, Lawson
    CURRENT ONCOLOGY, 2022, 29 (09) : 6260 - 6276
  • [10] Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer
    Cunha, R.
    Fernandes, M.
    Abreu, S.
    Oliveira, C.
    Dias, J.
    Alves, S.
    Rodrigues, A.
    Oliveira, J.
    Pousa, M. I.
    Soares, M.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S1432 - S1432
12345